|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Farxiga
|
|
gptkbp:activities
|
gptkb:drug
|
|
gptkbp:approves
|
gptkb:United_States
|
|
gptkbp:brand
|
gptkb:Invokana
|
|
gptkbp:category
|
gptkb:C
not recommended
|
|
gptkbp:clinical_trial
|
Phase 3
adjunct to diet and exercise
|
|
gptkbp:contraindication
|
dialysis
end-stage renal disease
severe renal impairment
|
|
gptkbp:counseling_services
|
hydration status
monitoring blood sugar levels
importance of adherence to therapy
risk of ketoacidosis
signs of urinary tract infection
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:effective_date
|
2013-03-29
|
|
gptkbp:form
|
300 mg tablet
100 mg tablet
|
|
gptkbp:formulation
|
canagliflozin and metformin
|
|
gptkbp:has_ability
|
100 mg
300 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Invokana
|
|
gptkbp:ingredients
|
canagliflozin
|
|
gptkbp:interacts_with
|
gptkb:Company
diuretics
other antidiabetic agents
|
|
gptkbp:invention
|
2026-03-29
|
|
gptkbp:is_monitored_by
|
renal function
blood glucose levels
|
|
gptkbp:is_used_for
|
type 2 diabetes
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Invokana
|
|
gptkbp:products
|
gptkb:Jardiance
gptkb:Farxiga
Steglatro
|
|
gptkbp:side_effect
|
dizziness
fatigue
nausea
vomiting
dehydration
constipation
hypoglycemia
urinary tract infection
thirst
genital yeast infection
|